The DYRK1A Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disrupting the DYRK1A gene in the HAP1 human near-haploid cell line. This polyclonal knockout product provides a heterogeneous loss-of-function model for investigating DYRK1A-dependent cellular processes, offering a powerful tool for genetic and pharmacological studies without the limitations of single-cell clonal selection. The CRISPR/Cas9-mediated gene disruption abrogates DYRK1A protein expression, enabling researchers to dissect its role in proliferation, differentiation, and signal transduction.
The HAP1 host cell line is a near-haploid, adherent, fibroblastoid cell line derived from the KBM-7 chronic myeloid leukemia line. Its haploid karyotype simplifies genetic manipulation and phenotypic analysis, as only one allele requires targeting to achieve functional gene disruption, thereby eliminating compensatory effects from a second allele. This feature renders HAP1 cells an ideal platform for high-throughput genetic screens, CRISPR-based functional genomics, and detailed mechanistic studies of kinase signaling pathways.
DYRK1A encodes a proline-directed serine/threonine kinase that phosphorylates substrates to regulate cell cycle, neuronal differentiation, and synaptic plasticity. DYRK1A is activated by autophosphorylation and is modulated by the DCAF7/WDR68 complex and stress signals. Key phosphorylated targets include NFATc1, tau, STAT3, and cyclin D1, leading to NFAT pathway inhibition, tau hyperphosphorylation, and cell cycle control. DYRK1A interacts with 14-3-3 proteins and integrates signals from RAS and HIPK2 to coordinate Wnt/??-catenin signaling and circadian rhythm via CRY2. Thus, DYRK1A functions as a critical signaling hub.
In the context of the near-haploid HAP1 line, DYRK1A knockout eliminates kinase activity without interference from a wild-type allele, providing an unambiguous loss-of-function background for studying DYRK1A-dependent signaling. This model is particularly relevant for dissecting gene dosage effects, as DYRK1A overexpression in trisomy 21 is implicated in Down syndrome?Cassociated cognitive deficits and early-onset Alzheimer??s disease neuropathology. The HAP1 DYRK1A knockout cells enable precise quantification of phospho-substrate levels, evaluation of kinase inhibitor selectivity, and assessment of DYRK1A??s role in cell proliferation and cell cycle exit, all within a genetically streamlined system.
These polyclonal knockout cells are suitable for assays including Western blotting for phospho-tau and NFATc1, RT-qPCR of NFAT target genes, immunofluorescence for nuclear NFAT, kinase activity assays, proliferation measurements, and neurite outgrowth assays. Applications include Down syndrome modeling, Alzheimer??s research, neurodevelopmental disorders, kinase inhibitor screening, and gene dosage studies. For further information, please contact Ascent Research.
